IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v609y2022i7929d10.1038_s41586-022-05287-8.html
   My bibliography  Save this article

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Author

Listed:
  • Daniel Zingg

    (Netherlands Cancer Institute
    Oncode Institute)

  • Jinhyuk Bhin

    (Netherlands Cancer Institute
    Oncode Institute
    Netherlands Cancer Institute)

  • Julia Yemelyanenko

    (Netherlands Cancer Institute
    Oncode Institute)

  • Sjors M. Kas

    (Netherlands Cancer Institute
    Oncode Institute)

  • Frank Rolfs

    (Netherlands Cancer Institute
    Oncode Institute
    Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam)

  • Catrin Lutz

    (Netherlands Cancer Institute
    Oncode Institute)

  • Jessica K. Lee

    (Foundation Medicine)

  • Sjoerd Klarenbeek

    (Netherlands Cancer Institute)

  • Ian M. Silverman

    (Incyte Research Institute)

  • Stefano Annunziato

    (Netherlands Cancer Institute
    Oncode Institute)

  • Chang S. Chan

    (Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
    Rutgers University)

  • Sander R. Piersma

    (Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam)

  • Timo Eijkman

    (Netherlands Cancer Institute
    Oncode Institute)

  • Madelon Badoux

    (Netherlands Cancer Institute
    Oncode Institute)

  • Ewa Gogola

    (Netherlands Cancer Institute
    Oncode Institute)

  • Bjørn Siteur

    (Netherlands Cancer Institute)

  • Justin Sprengers

    (Netherlands Cancer Institute)

  • Bim Klein

    (Netherlands Cancer Institute
    Oncode Institute)

  • Richard R. Goeij-de Haas

    (Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam)

  • Gregory M. Riedlinger

    (Rutgers University
    Rutgers Cancer Institute of New Jersey)

  • Hua Ke

    (Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
    Rutgers University)

  • Russell Madison

    (Foundation Medicine)

  • Anne Paulien Drenth

    (Netherlands Cancer Institute
    Oncode Institute)

  • Eline Burg

    (Netherlands Cancer Institute
    Oncode Institute)

  • Eva Schut

    (Netherlands Cancer Institute
    Oncode Institute)

  • Linda Henneman

    (Netherlands Cancer Institute
    Oncode Institute
    Netherlands Cancer Institute)

  • Martine H. Miltenburg

    (Netherlands Cancer Institute
    Oncode Institute)

  • Natalie Proost

    (Netherlands Cancer Institute)

  • Huiling Zhen

    (Incyte)

  • Ellen Wientjens

    (Netherlands Cancer Institute
    Oncode Institute)

  • Roebi Bruijn

    (Netherlands Cancer Institute
    Oncode Institute
    Netherlands Cancer Institute)

  • Julian R. Ruiter

    (Netherlands Cancer Institute
    Oncode Institute
    Netherlands Cancer Institute)

  • Ute Boon

    (Netherlands Cancer Institute
    Oncode Institute)

  • Renske Korte-Grimmerink

    (Netherlands Cancer Institute)

  • Bastiaan Gerwen

    (Netherlands Cancer Institute)

  • Luis Féliz

    (Incyte Biosciences International)

  • Ghassan K. Abou-Alfa

    (Memorial Sloan Kettering Cancer Center
    Weill Medical College at Cornell University)

  • Jeffrey S. Ross

    (Foundation Medicine
    Upstate Medical University)

  • Marieke Ven

    (Netherlands Cancer Institute)

  • Sven Rottenberg

    (Netherlands Cancer Institute
    University of Bern
    University of Bern)

  • Edwin Cuppen

    (Oncode Institute
    Hartwig Medical Foundation
    University Medical Center Utrecht)

  • Anne Vaslin Chessex

    (Debiopharm International)

  • Siraj M. Ali

    (Foundation Medicine)

  • Timothy C. Burn

    (Incyte Research Institute)

  • Connie R. Jimenez

    (Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam)

  • Shridar Ganesan

    (Division of Medical Oncology, Rutgers Cancer Institute of New Jersey
    Rutgers University)

  • Lodewyk F. A. Wessels

    (Oncode Institute
    Netherlands Cancer Institute)

  • Jos Jonkers

    (Netherlands Cancer Institute
    Oncode Institute)

Abstract

No abstract is available for this item.

Suggested Citation

  • Daniel Zingg & Jinhyuk Bhin & Julia Yemelyanenko & Sjors M. Kas & Frank Rolfs & Catrin Lutz & Jessica K. Lee & Sjoerd Klarenbeek & Ian M. Silverman & Stefano Annunziato & Chang S. Chan & Sander R. Pie, 2022. "Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers," Nature, Nature, vol. 609(7929), pages 13-13, September.
    • Handle: RePEc:nat:nature:v:609:y:2022:i:7929:d:10.1038_s41586-022-05287-8
    DOI: 10.1038/s41586-022-05287-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-022-05287-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/s41586-022-05287-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Yuanli Zhen & Kai Liu & Lei Shi & Simran Shah & Qin Xu & Haley Ellis & Eranga R. Balasooriya & Johannes Kreuzer & Robert Morris & Albert S. Baldwin & Dejan Juric & Wilhelm Haas & Nabeel Bardeesy, 2024. "FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma," Nature Communications, Nature, vol. 15(1), pages 1-17, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:609:y:2022:i:7929:d:10.1038_s41586-022-05287-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.